Ongoing Disclosure Notices - Options, PSRs, Ordinary Shares

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:9 September 2026
Date of last disclosure: 3 September 2026
Director or senior manager giving disclosure
Full name(s):Andrew Robert Donald Somervell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Performance Share Rights
Nature of the affected relevant interest(s):Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:46,615 Performance Share Rights
Number held in class after acquisition or disposal:
66,418 Performance Share Rights
Current registered holder(s):Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
8 September 2026
Nature of transaction: Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
Nil
Number of financial products to which the transaction related:
19,803 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Ordinary Shares
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 64,269 Options to acquire Ordinary Shares
b) 146,624 Ordinary Shares
Current registered holder(s):
Andrew Robert Donald Somervell
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:9 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:9 September 2026
Date of last disclosure: 3 September 2026
Director or senior manager giving disclosure
Full name(s):
Andrew Grant Niccol
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Operating Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
a) Performance Share Rights
b) Ordinary Shares
Nature of the affected relevant interest(s):Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
a) 18,126 Performance Share Rights
b) 7,376 Ordinary Shares
Number held in class after acquisition or disposal:
a) 30,272 Performance Share Rights
b) 2,976 Ordinary Shares
Current registered holder(s):
Andrew Grant Niccol
Registered holder(s) once transfers are registered:
Andrew Grant Niccol
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Four
Details of transactions requiring disclosure-
Date of transaction:
a) 8 September 2026
b) 8 September 2026
c) 7 September 2026
d) 4 September 2026
Nature of transaction:
a) Issue of Performance Share Rights
b) Sale of Ordinary Shares
c) Sale of Ordinary Shares
d) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
a) Nil
b) $44.0700 per Ordinary Share
c) $44.3600 per Ordinary Share
d) $44.8400 per Ordinary Share
Number of financial products to which the transaction related:
a) 12,146 Performance Share Rights
b) 1,400 Ordinary Shares
c) 2,000 Ordinary Shares
d) 1,000 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Options to acquire Ordinary Shares
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
18,345 Options to acquire Ordinary Shares
Current registered holder(s):Andrew Grant Niccol
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:9 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
9 September 2026
Date of last disclosure:
3 September 2026
Director or senior manager giving disclosure
Full name(s):
Justin Peter Callahan
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
a) 89,472 Options to acquire Ordinary Shares
b) 64,091 Performance Share Rights
Number held in class after acquisition or disposal:
a) 115,662 Options to acquire Ordinary Shares
b) 94,597 Performance Share Rights
Current registered holder(s):
Justin Peter Callahan
Registered holder(s) once transfers are registered:
Justin Peter Callahan
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Two
Details of transactions requiring disclosure-
Date of transaction:
a) 8 September 2026
b) 8 September 2026
Nature of transaction:
a) Issue of Options to acquire Ordinary Shares
b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
a) Nil
b) Nil

Number of financial products to which the transaction related:
a) 26,190 Options to acquire Ordinary Shares
b) 30,506 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary Shares
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
221,009 Ordinary Shares
Current registered holder(s):Justin Peter Callahan
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
9 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:9 September 2026
Date of last disclosure: 3 September 2026
Director or senior manager giving disclosure
Full name(s):
Lewis George Gradon
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Performance Share Rights
Nature of the affected relevant interest(s):Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:145,013 Performance Share Rights
Number held in class after acquisition or disposal:208,815 Performance Share Rights
Current registered holder(s):Lewis George Gradon
Registered holder(s) once transfers are registered:Lewis George Gradon
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One

Details of transactions requiring disclosure-
Date of transaction:
8 September 2026
Nature of transaction:
Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
Nil
Number of financial products to which the transaction related:
63,802 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Ordinary Shares
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 198,657 Options to acquire Ordinary Shares
b) 558,934 Ordinary Shares
Current registered holder(s):
a) Lewis George Gradon
b) Lewis George Gradon; Gradon Family Trust
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
9 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
9 September 2026
Date of last disclosure:
3 September 2026
Director or senior manager giving disclosure
Full name(s):
Lyndal Jane York
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Performance Share Rights
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
74,216 Performance Share Rights
Number held in class after acquisition or disposal:
109,223 Performance Share Rights
Current registered holder(s):Lyndal Jane York
Registered holder(s) once transfers are registered:Lyndal Jane York
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
8 September 2026
Nature of transaction:
Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
Nil
Number of financial products to which the transaction related:
35,007 Performance Share Rights

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Ordinary Shares
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 101,299 Options to acquire Ordinary Shares
b) 52,617 Ordinary Shares
Current registered holder(s):
a) Lyndal Jane York
b) Lyndal Jane York and Alexander Eric York
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
9 September 2026
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary